Evidence Snapshot

Histone deacetylase 6

CHEMBL1865 SINGLE PROTEIN Homo sapiens

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:14:24Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 12:14 PM KST As of · Sep 14, 2026

ChEMBL ChEMBL 36 CHEMBL1865

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Histone deacetylase 6 as ChEMBL target CHEMBL1865, mapped to UniProt Q9UBN7. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

Histone deacetylase 6

SINGLE PROTEIN · Homo sapiens

As of 2026-09-14

ChEMBL target ID

CHEMBL1865

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-14

www.ebi.ac.uk

UniProt accession

Q9UBN7

Protein deacetylase HDAC6

UniProt accession via ChEMBL component mapping As of 2026-09-14

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-14

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Histone deacetylase 6 matters

As of 2026-09-14

Histone deacetylase 6 is reviewed as Protein deacetylase HDAC6 (UniProt Q9UBN7); Histone deacetylase 6 shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 36 approved drugs, 13806 compounds, and 1862 assays, with lead potency reaching pChEMBL 10.1.

Protein context

Protein deacetylase HDAC6

Protein deacetylase HDAC6 Sequence length is 1215 aa.

Review this target as Histone deacetylase 6, mapped to UniProt Q9UBN7. ChEMBL maps the protein component as Protein deacetylase HDAC6. Sequence length is 1215 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt Q9UBN7 Protein

Disease context

cancer

Histone deacetylase 6 shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include VORINOSTAT.

Start review with cancer because it currently carries approved-linked support. Linked drugs include VORINOSTAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Approved-linked 1 linked drug

Activity base

Portfolio and assay base

ChEMBL currently tracks 36 approved drugs, 13806 compounds, and 1862 assays for this target. The dominant activity type is IC50. CHEMBL4082520 is the current potency anchor at pChEMBL 10.1.

Use CHEMBL4082520 as the tractability anchor when discussing potency (pChEMBL 10.1).

Activity source · ChEMBL 36 via Core Engine

36 approved pChEMBL 10.1

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Histone deacetylase 6 matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q9UBN7, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why cancer is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

13806

Total Compounds

1862

Total Assays

Approved Drugs

IC50: 9628.0, KI: 196.0, EC50: 101.0, KD: 128.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Compound	pChEMBL	Type	Phase
No preferred name CHEMBL4082520	10.1	Ki	—
No preferred name CHEMBL4290831	10.0	IC50	—
No preferred name CHEMBL5195946	10.0	IC50	—
No preferred name CHEMBL99	9.9	Ki	—
No preferred name CHEMBL4098975	9.8	IC50	—